New system for assessing the prognosis of refractory anemia patients

New system for assessing the prognosis of refractory anemia patients
复制标题

评估难治性贫血患者预后的新系统

DOI:
10.1038/sj.leu.2401556
复制
发表时间:
1999
期刊:
影响因子:
11.4
通讯作者:
M. Tomonaga
M. Tomonaga
中科院分区:
医学1区
文献类型:
--
作者:
A. Matsuda;I. Jinnai;F. Yagasaki;S. Kusumoto;I. Murohashi;M. Bessho;K. Hirashima;S. Honda;M. Minamihisamatsu;K. Fuchigami;T. Matsuo;K. Kuriyama;M. Tomonaga

文献摘要

参考文献

被引文献

相似文献

难治性贫血(RA)是一种在生物学和临床特征上具有很强异质性的疾病。国际预后评分系统(IPSS)对219例骨髓增生异常综合征(MDS)患者的预后进行了评估。然而,132例RA患者的IPSS不够充分。为了预测急性髓系白血病(AML)患者的生存和免于进展,我们基于132例RA患者的临床参数(年龄、性别、形态特征、细胞减少和细胞遗传学),采用单因素和多因素分析对个体预后因素进行了研究。根据这一结果,我们设计了一种新的评估RA患者预后的系统。在我们的系统中,假性⩾异常⩾为3%的RA患者被归类为高危患者(12例),在无PP异常的患者中,根据IPSS、Hb⩽6 g/dl或⩾10%核型中/差的患者被归类为中危患者(57例),而无高或中危患者被归类为低危患者(67例)。在我们的系统中,生存时间和无白血病生存时间的分析显示,三组之间存在显著差异(P<0.0001)。
Refractory anemia (RA) is a very heterogeneous disease regarding biological and clinical features. The International Prognostic Scoring System (IPSS) was useful for assessing the prognosis in the whole group of 219 myelodysplastic syndrome (MDS) patients. However, the IPSS was not sufficient in 132 RA patients. To predict survival and freedom from acute myeloid leukemia (AML) evolution, we investigated individual prognostic factors based on the clinical parameters (age, gender, morphologic features, cytopenias and cytogenetics) of 132 RA patients using univariate and multivariate analyses. Based on the results, we devised a new system for assessing the prognosis of RA patients. In our system, RA patients with pseudo-Pelger-Huët anomalies ⩾3% were classified as high risk (12 patients); of patients without pseudo-Pelger–Huët anomalies ⩾3%, those with intermediate/poor karyotype according to IPSS, Hb ⩽6 g/dl or mMgk ⩾10% were classified as intermediate risk (57 patients); and those without high or intermediate risk were classified as low risk (67 patients). In our system, the analyses of both survival times and leukemia-free survival times revealed significant differences among the three groups (P < 0.0001).
DOI: --
发表时间: 1996
期刊: Leukemia
影响因子: 11.4
作者:
S. Rosati;R. Mick;F. Xu;E. Stonys;M. L. Beau;R. Larson;J. Vardiman
通讯作者: S. Rosati;R. Mick;F. Xu;E. Stonys;M. L. Beau;R. Larson;J. Vardiman